WIP1 phosphatase as pharmacological target in cancer therapy

Wip 1 inhibits intestinal inflammation in inflammatory bowel disease

(2016) Qi Zhang et al.   CELLULAR IMMUNOLOGY

Truncating and missensePPM1Dmutations in early-onset and/or familial/hereditary prostate cancer patients

(2016) Marta Cardoso et al.   GENES CHROMOSOMES & CANCER

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner

(2016) A. Esfandiari et al.   MOLECULAR CANCER THERAPEUTICS

MDM2 oligomers: antagonizers of the guardian of the genome

(2016) P L Leslie et al.   ONCOGENE

Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy

(2016) V Clausse et al.   Cell Death & Disease

TP53 mutations, expression and interaction networks in human cancers

(2016) Xiaosheng Wang et al.   Oncotarget

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53

(2016) Chinami Makii et al.   Oncotarget

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma

(2016) Kensuke Kojima et al.   Oncotarget

Somatic Mosaic Mutations inPPM1DandTP53in the Blood of Women With Ovarian Carcinoma

(2016) Elizabeth M. Swisher et al.   JAMA Oncology

Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis

(2016) Zhenghu Chen et al.   Scientific Reports

Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation

(2015) Sari Ogasawara et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Phosphatase Wip1 controls antigen-independent B-cell development in a p53-dependent manner

(2015) W. Yi et al.   BLOOD

Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients

(2015) A Zajkowicz et al.   BRITISH JOURNAL OF CANCER

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines

(2015) Derek Edwardson et al.   CURRENT DRUG METABOLISM

The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle

(2015) I. A. Shaltiel et al.   JOURNAL OF CELL SCIENCE

CRISPR-Cas9–based target validation for p53-reactivating model compounds

(2015) Michael Wanzel et al.   Nature Chemical Biology

Cancer whole-genome sequencing: present and future

(2015) H Nakagawa et al.   ONCOGENE

Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms

(2015) Luc Rochette et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Wip1 deficiency impairs haematopoietic stem cell function via p53 and mTORC1 pathways

(2015) Zhiyang Chen et al.   Nature Communications

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

(2015) Lindi Chen et al.   Oncotarget

WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma

(2015) Mark Richter et al.   PLoS One

Regulation of p53: a collaboration between Mdm2 and Mdmx

(2015) Dongsheng Pei et al.   Oncotarget

Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line

(2014) Yuuki Kozakai et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Wild-type p53-induced phosphatase 1 (Wip1) forestalls cellular premature senescence at physiological oxygen levels by regulating DNA damage response signaling during DNA replication

(2014) Hiroyasu Sakai et al.   CELL CYCLE

Nuclear translocation of Cyclin B1 marks the restriction point for terminal cell cycle exit in G2 phase

(2014) Erik Müllers et al.   CELL CYCLE

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

(2014) B. Higgins et al.   CLINICAL CANCER RESEARCH

Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor

(2014) Lingyun Qin et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Transient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence

(2014) Lenno Krenning et al.   MOLECULAR CELL

Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction

(2014) Aidan G Gilmartin et al.   Nature Chemical Biology

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas

(2014) Liwei Zhang et al.   NATURE GENETICS

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

Distinct phosphatases antagonize the p53 response in different phases of the cell cycle

(2014) I. A. Shaltiel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Wip1 Controls Global Heterochromatin Silencing via ATM/BRCA1-Dependent DNA Methylation

(2013) Doria Filipponi et al.   CANCER CELL

Downregulation of Wip1 phosphatase modulates the cellular threshold of DNA damage signaling in mitosis

(2013) Libor Macurek et al.   CELL CYCLE

Genetic variants and mutations ofPPM1Dcontrol the response to DNA damage

(2013) Crissy Dudgeon et al.   CELL CYCLE

Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint

(2013) Petra Kleiblova et al.   JOURNAL OF CELL BIOLOGY

Off-target response of a Wip1 chemical inhibitor in skin keratinocytes

(2013) Ji-Seon Lee et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

WIP1, a Homeostatic Regulator of the DNA Damage Response, Is Targeted by HIPK2 for Phosphorylation and Degradation

(2013) Dong Wook Choi et al.   MOLECULAR CELL

Synergistic and tunable human gene activation by combinations of synthetic transcription factors

(2013) Pablo Perez-Pinera et al.   NATURE METHODS

Wip1 suppresses apoptotic cell death through direct dephosphorylation of BAX in response to γ-radiation

(2013) J-Y Song et al.   Cell Death & Disease

Towards structure-based protein drug design

(2012) Changsheng Zhang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Over-expression of Wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas

(2012) Chaohui Liang et al.   BRAIN RESEARCH

Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xLratio

(2012) Anastasia R. Goloudina et al.   CELL CYCLE

Playing the End Game: DNA Double-Strand Break Repair Pathway Choice

(2012) J. Ross Chapman et al.   MOLECULAR CELL

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

(2012) Elise Ruark et al.   NATURE

Optimization of a Cyclic Peptide Inhibitor of Ser/Thr Phosphatase PPM1D (Wip1)

(2011) Ryo Hayashi et al.   BIOCHEMISTRY

A small molecule inhibitor of p53-inducible protein phosphatase PPM1D

(2011) Hiroaki Yagi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival

(2011) Naoyuki Satoh et al.   CANCER SCIENCE

Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications

(2011) S. E. Polo et al.   GENES & DEVELOPMENT

The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation

(2011) A Y Ali et al.   ONCOGENE

Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents

(2011) A. R. Goloudina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1

(2011) Melanie Blasius et al.   GENOME BIOLOGY

Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax

(2010) Weihong Kong et al.   CANCER BIOLOGY & THERAPY

Wip1 Directly Dephosphorylates  -H2AX and Attenuates the DNA Damage Response

(2010) H. Cha et al.   CANCER RESEARCH

The Wip1 phosphatase and Mdm2: Cracking the "Wip" on p53 stability

(2010) Xiongbin Lu et al.   CELL CYCLE

Weak p53 permits senescence during cell cycle arrest

(2010) Olga V. Leontieva et al.   CELL CYCLE

The oncogenic phosphatase WIP1 negatively regulates nucleotide excision repair

(2010) Thuy-Ai Nguyen et al.   DNA REPAIR

Wild-type p53-induced Phosphatase 1 Dephosphorylates Histone Variant γ-H2AX and Suppresses DNA Double Strand Break Repair

(2010) Sung-Hwan Moon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Wip1 phosphatase is associated with chromatin and dephosphorylates γH2AX to promote checkpoint inhibition

(2010) L Macůrek et al.   ONCOGENE

Phosphorylation and Degradation of MdmX Is Inhibited by Wip1 Phosphatase in the DNA Damage Response

(2009) X. Zhang et al.   CANCER RESEARCH

Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers

(2009) R. Natrajan et al.   CLINICAL CANCER RESEARCH

PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas

(2009) D. S.P. Tan et al.   CLINICAL CANCER RESEARCH

Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression

(2009) Arne Lindqvist et al.   EMBO JOURNAL

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

WIP1 phosphatase is a negative regulator of NF-κB signalling

(2009) Joanne Chew et al.   NATURE CELL BIOLOGY

Cell fate decision mediated by p53 pulses

(2009) X.-P. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Senescent Growth Arrest in Mesenchymal Stem Cells Is Bypassed by Wip1-Mediated Downregulation of Intrinsic Stress Signaling Pathways

(2009) Ji-Seon Lee et al.   STEM CELLS

WIP1 phosphatase at the crossroads of cancer and aging

(2009) Xavier Le Guezennec et al.   TRENDS IN BIOCHEMICAL SCIENCES

The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways

(2008) Xiongbin Lu et al.   CANCER AND METASTASIS REVIEWS

PPM1D430, a Novel Alternative Splicing Variant of the Human PPM1D, can Dephosphorylate p53 and Exhibits Specific Tissue Expression

(2008) Y. Chuman et al.   JOURNAL OF BIOCHEMISTRY

Arsenic Trioxide Augments Chk2/p53-mediated Apoptosis by Inhibiting Oncogenic Wip1 Phosphatase

(2008) Akinori Yoda et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Characterization of the Active Site and a Unique Uncompetitive Inhibitor of the PPM1-Type Protein Phosphatase PPM1D

(2008) Yoshiro Chuman et al.   PROTEIN AND PEPTIDE LETTERS

An Oncogene-Induced DNA Damage Model for Cancer Development

(2008) T. D. Halazonetis et al.   SCIENCE

A Small Molecular Scaffold for Selective Inhibition of Wip1 Phosphatase

(2007) Jeong Bang et al.   ChemMedChem